| Primary |
| Analgesic Therapy |
17.6% |
| Pneumonia |
17.6% |
| Anaesthesia |
11.8% |
| Arthralgia |
11.8% |
| Lung Disorder |
11.8% |
| Product Used For Unknown Indication |
11.8% |
| Thrombosis Prophylaxis |
11.8% |
| Asthma |
5.9% |
|
| Neutropenia |
50.0% |
| Eosinophilia |
25.0% |
| Proteinuria |
25.0% |
|
| Secondary |
| Product Used For Unknown Indication |
44.3% |
| Drug Use For Unknown Indication |
9.5% |
| Lung Disorder |
5.9% |
| Cardiac Failure |
4.4% |
| Haemolytic Uraemic Syndrome |
4.2% |
| Atrial Fibrillation |
3.6% |
| Bronchitis |
3.2% |
| Pneumonia |
3.2% |
| Hypertension |
2.8% |
| Interstitial Lung Disease |
2.8% |
| Thrombosis Prophylaxis |
2.1% |
| Hypothyroidism |
1.9% |
| Bipolar Disorder |
1.7% |
| Diabetes Mellitus |
1.7% |
| Blood Culture Positive |
1.5% |
| Epilepsy |
1.5% |
| Pain |
1.5% |
| Prophylaxis |
1.5% |
| Rheumatoid Arthritis |
1.5% |
| General Physical Health Deterioration |
1.3% |
|
| Thrombocytopenia |
12.5% |
| Purpura |
10.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
7.8% |
| Acute Generalised Exanthematous Pustulosis |
6.3% |
| Meningitis Aseptic |
6.3% |
| Cardio-respiratory Arrest |
4.7% |
| Cytolytic Hepatitis |
4.7% |
| Haematoma |
4.7% |
| Hepatitis Acute |
4.7% |
| Neutropenia |
4.7% |
| Rash Pruritic |
4.7% |
| Bone Marrow Disorder |
3.1% |
| Bone Marrow Toxicity |
3.1% |
| Condition Aggravated |
3.1% |
| Hypovolaemic Shock |
3.1% |
| International Normalised Ratio Increased |
3.1% |
| Lung Disorder |
3.1% |
| Pancytopenia |
3.1% |
| Pneumonia |
3.1% |
| Pyrexia |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.9% |
| Drug Use For Unknown Indication |
9.9% |
| Acute Myeloid Leukaemia |
7.4% |
| Induction Of Anaesthesia |
7.1% |
| Pyrexia |
4.9% |
| Chronic Myeloid Leukaemia |
4.6% |
| Acute Lymphocytic Leukaemia |
4.2% |
| Thrombosis Prophylaxis |
3.9% |
| Pneumonia |
3.5% |
| Lung Infection |
3.2% |
| Lung Disorder |
2.8% |
| Brain Abscess |
2.5% |
| Encephalitis |
2.5% |
| Infection |
2.5% |
| Prophylaxis |
2.5% |
| Aspergillosis |
2.1% |
| Cancer Pain |
2.1% |
| Coronary Artery Bypass |
2.1% |
| Myeloma |
2.1% |
| Pain |
2.1% |
|
| Thrombocytopenia |
9.8% |
| Anaemia |
7.8% |
| Myocardial Infarction |
7.8% |
| Renal Failure Acute |
7.8% |
| Serratia Infection |
5.9% |
| Toxic Skin Eruption |
5.9% |
| Bronchospasm |
3.9% |
| Coma |
3.9% |
| Cytolytic Hepatitis |
3.9% |
| Dermatitis Exfoliative |
3.9% |
| Hallucination, Auditory |
3.9% |
| Hepatocellular Damage |
3.9% |
| International Normalised Ratio Increased |
3.9% |
| Maternal Exposure During Pregnancy |
3.9% |
| Mixed Liver Injury |
3.9% |
| Myalgia |
3.9% |
| Neuropathy Peripheral |
3.9% |
| Osteoporosis |
3.9% |
| Pain |
3.9% |
| Pancreatitis |
3.9% |
|
| Interacting |
| Septic Shock |
28.6% |
| Allergic Granulomatous Angiitis |
14.3% |
| Hypokalaemia |
14.3% |
| Immunosuppression |
10.7% |
| Atrial Fibrillation |
7.1% |
| Hypercholesterolaemia |
7.1% |
| Infection |
7.1% |
| Osteoporosis |
7.1% |
| Bronchitis |
3.6% |
|
| Drug Interaction |
50.0% |
| Abdominal Wall Haematoma |
33.3% |
| Allergic Granulomatous Angiitis |
16.7% |
|
